Canaccord lowered the firm’s price target on iRhythm to $122 from $133 and keeps a Buy rating on the shares. The firm said they posted a Q1 beat and there were no notable changes withthe company continuing its work on clearing the warning letter, seeing continued traction in the PCP channel, OUS expansion, launching Know Your Rhythm, and piloting sleep apnea.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRTC:
- iRhythm Technologies to Report First Quarter 2024 Financial Results on May 2, 2024
- Class Action Suit against iRhythm Technologies, Inc. (IRTC)
- iRhythm Announces Closing of $661.25 Million of 1.50% Convertible Senior Notes Due 2029, Including Full Exercise of Initial Purchasers’ $86.25 Million Option to Purchase Additional Notes
- iRhythm Prices Upsized Offering of $575.0 Million of 1.50% Convertible Senior Notes Due 2029
- iRhythm Announces Proposed Offering of $450.0 Million of Convertible Senior Notes